774609-73-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
Tert-Butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new molecules with potential therapeutic and pesticidal properties.
Used in Enzyme Inhibition Research:
tert-Butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate is employed as an enzyme inhibitor in drug development. Its ability to inhibit certain enzymes makes it a valuable tool in the discovery of new drugs targeting specific biological pathways.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In the field of organic chemistry, Tert-Butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate is used as a chiral auxiliary. It aids in the production of enantiomerically pure compounds, which is crucial for the synthesis of biologically active molecules with specific stereochemistry.
Used in the Development of Novel Drug Delivery Systems:
tert-Butyl 4-(cyanomethyl)-4-hydroxypiperidine-1-carboxylate's potential in the development of drug delivery systems is being explored to enhance the bioavailability and therapeutic efficacy of drugs. Its incorporation into these systems can improve drug targeting and reduce side effects.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 75-05-8 acetonitrile 
• 590-17-0 cyanomethyl bromide 

Downstream Products

• 1209319-87-8 2-oxo-1-oxa-3,9-diazaspiro[5.5]undecane-9-formic acid tert-butyl ester 

Relevant academic research and scientific papers

Cyano-substituted cyclic hydrazine derivatives and application thereof

The invention provides cyano-substituted cyclic hydrazine derivatives. The cyano-substituted cyclic hydrazine derivatives are characterized in that the cyano-substituted cyclic hydrazine derivatives are compounds as shown in the following structural formula shown in the specification or stereoisomers, geometrical isomers, tautomers, racemates, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof; the compounds are useful for the prevention, treatment, treatment or amelioration of autoimmune diseases or proliferative diseases in patients, and/or for the inhibition or modulation of protein kinase activity.

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS

This invention relates to novel compounds of formula (I), which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

ANTIBACTERIAL AGENTS

Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.